| ²é¿´: 1570 | »Ø¸´: 5 | ||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||
cpu0442807гæ (³õÈëÎÄ̳)
|
[ÇóÖú]
ÇóÖúActemra£¨Tocilizumab£©Ô¤¹à×°¼ÁÐ͵ľßÌå´¦·½ ÒÑÓÐ1È˲ÎÓë
|
|
| ±¾ÈËÊÇ×öÒ©ÎïÖÆ¼ÁµÄ£¬×î½üÔÚ¹Ø×¢ÂÞÊϹ«Ë¾µÄActemraÕâ¸öÒ©Î¸ÃÒ©ÓÐÁ½ÖÖ¼ÁÐÍ£ºÆ¿×°ºÍÔ¤¹à×°£¬µ«ÊÇÍøÉϵÄ×ÊÁÏÖÐÖ»ÓÐÆ¿×°µÄÏêϸ´¦·½£¬Ô¤¹à×°µÄ´¦·½ÔòÖ»Äܲ鵽Ïà¹ØµÄ¸¨ÁÏÃû³Æ£¬ÕÒ²»µ½¾ßÌåµÄŨ¶ÈÐÅÏ¢£¬Ï£ÍûÓкÃÐÄÈËÄܰïÎÒ½â»ó£¬×îºÃÄܸ½Éϳö´¦£¬Ð»Ð»£¡ |
» ²ÂÄãϲ»¶
26ÔÚÖ°É격¡ªÉúÎïÓëÒ½Ò©¡ª¿¹Ìå/ADCÒ©Îï·½Ïò£¬½Õ㻦£¬ÓÐÏîÄ¿£¬¿É´ø×Ê¡£
ÒѾÓÐ1È˻ظ´
288·ÖÇóµ÷¼Á
ÒѾÓÐ0È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ120È˻ظ´
¹ãÎ÷Ò½¿Æ´óѧ»ù´¡Ò½Ñ§Ôº×ÔÉíÃâÒß²¡¿ÎÌâ×éÕÐÊÕ»ù´¡Ò½Ñ§Ïà¹Ø×¨ÒµµÄµ÷¼ÁÑо¿Éú
ÒѾÓÐ2È˻ظ´
Ò»Ö¾Ô¸ËÕÖÝ´óѧ ÉúÎï¼¼ÊõÓ빤³Ì£¨086001£© ³õÊÔ323·Ö£¬Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
ÈýÄêʵÑéÊÒ¹¤×÷¾Àú£¬Ò»Ö¾Ô¸»ªÖÐũҵ´óѧ΢ÉúÎ×Ü·Ö288Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
070700Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
Çóµ÷¼Á×Ü·Ö327
ÒѾÓÐ1È˻ظ´
¹ãÎ÷Ò½¿Æ´óѧ»ù´¡Ò½Ñ§ÔºÕÐÊÕ»ù´¡Ò½Ñ§¡¢Ò©Ñ§¡¢ÉúÎï¼ìÑéÏà¹Ø×¨ÒµµÄÑо¿Éú
ÒѾÓÐ1È˻ظ´
BL21(DE3)UV»òÕßË¿ÁÑÃ¹ËØÓÕµ¼Ìõ¼þÏ»áÊÍ·ÅDE3µÄÊɾúÌåÂð£¿
ÒѾÓÐ479È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ÇóÖúTocilizumab£¨ACTEMRA£© µÄ²úÆ·ÐòÁÐ
ÒѾÓÐ0È˻ظ´
cpu0442807
гæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 35.1
- Ìû×Ó: 17
- ÔÚÏß: 4.8Сʱ
- ³æºÅ: 1545383
- ×¢²á: 2011-12-20
- רҵ: ÉúÎï¼¼ÊõÒ©Îï
5Â¥2015-04-29 21:00:41
|
±¾ÌûÄÚÈݱ»ÆÁ±Î |
2Â¥2015-04-21 08:59:41
cc3135526
Òø³æ (ÕýʽдÊÖ)
- Ó¦Öú: 8 (Ó×¶ùÔ°)
- ½ð±Ò: 160.1
- ºì»¨: 1
- Ìû×Ó: 315
- ÔÚÏß: 143.3Сʱ
- ³æºÅ: 1151526
- ×¢²á: 2010-11-20
- רҵ: ÉúÎï´ó·Ö×ӽṹÓ빦ÄÜ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
cpu0442807: ½ð±Ò+5, ¡ïÓаïÖú, ллÄúÌṩµÄÐÅÏ¢£¬²»¹ý·¶Î§Ì«¿íÁË£¬Ï£ÍûÄÜÖªµÀÔÑÐÒ©ÖÐÈ·Çеĸ¨ÁÏŨ¶È¡£ 2015-04-21 14:31:49
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
cpu0442807: ½ð±Ò+5, ¡ïÓаïÖú, ллÄúÌṩµÄÐÅÏ¢£¬²»¹ý·¶Î§Ì«¿íÁË£¬Ï£ÍûÄÜÖªµÀÔÑÐÒ©ÖÐÈ·Çеĸ¨ÁÏŨ¶È¡£ 2015-04-21 14:31:49
|
ACTEMRA solution for subcutaneous administration is supplied as a sterile, colorless to yellowish, preservative-free liquid solution of approximately pH 6.0. It is supplied in a 1 mL ready-to-use, single-use prefilled syringe (PFS) with a needle safety device. Each device delivers 0.9 mL (162 mg) of ACTEMRA, in a histidine buffered solution composed of ACTEMRA (180 mg/mL), polysorbate 80, L-histidine and L-histidine monohydrochloride, L-arginine and L-arginine hydrochloride, L-methionine, and water for injection. ÒÔÉÏÊÇFDAÍøÕ¾ÉϹ«²¼µÄÕâЩÐÅÏ¢£¬ËäȻûÓÐд³ö¸÷¸ö¸¨ÁϵľßÌåŨ¶È£¬µ«ÊÇ¿ÉÒԲο¼ÆäËû¼¸¸ö¸ßŨ¶Èµ¥¿¹ÖƼÁ´¦·½£¬±ÈÈçSIMPONI (golimumab)£¬STELARA(ustekinumab)£¬»¹ÓÐGenetech×Ô¼ºµÄÒ»¸öרÀû£¨×¨ÀûºÅUS20090280129A1£©£¬L-histidine and L-histidine monohydrochloride£¨10-100mM, L-arginine and L-arginine hydrochloride(50-200mM), polysorbate 80 (0.01%-0.1%), Õâ¸öÔ¤¹à·âÖÆ¼ÁÀïÃæ»¹ÓиöL-methionine,Ó¦¸ÃÊÇΪÁ˼õÉÙ¸ßŨ¶ÈµÄ×ÔÓÉ»ùÑõ»¯£¬Å¨¶ÈÓ¦¸Ã²»»áÌ«¸ß¡£ |
3Â¥2015-04-21 09:28:49
cpu0442807
гæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 35.1
- Ìû×Ó: 17
- ÔÚÏß: 4.8Сʱ
- ³æºÅ: 1545383
- ×¢²á: 2011-12-20
- רҵ: ÉúÎï¼¼ÊõÒ©Îï
4Â¥2015-04-21 14:33:55









»Ø¸´´ËÂ¥
£¬Æ¿×°µÄ´¦·½ÎªÉ¶¾Í¿ÉÒÔ¹«¿ª£¬Õâ¸ö¾Í³É»úÃÜÁ˰¡
ͶƱ: